The role of NAD+ metabolic reprogramming in colorectal cancer chemoresistance: mechanistic insights, clinical translation challenges and opportunities - Report - MDSpire
Advertisement
The role of NAD+ metabolic reprogramming in colorectal cancer chemoresistance: mechanistic insights, clinical translation challenges and opportunities
Clinical Report: NAD+ Metabolic Reprogramming's Impact on Chemoresistance
Overview
NAD+ metabolic reprogramming plays a role in colorectal cancer chemoresistance by influencing energy metabolism, DNA repair, and the immune microenvironment. Targeted interventions against NAD+ metabolism are discussed in the context of emerging evidence.
Background
Colorectal cancer (CRC) is a prevalent and deadly malignancy, with chemoresistance being a major hurdle in treatment. Standard chemotherapy often leads to intrinsic or acquired resistance, complicating patient outcomes. The mechanisms behind chemoresistance, particularly the role of NAD+ metabolism, are explored.
Data Highlights
No numerical data or trial results were provided in the source material.
Key Findings
NAD+ metabolic reprogramming is a key driver of chemoresistance in colorectal cancer.
Key enzymes like NAMPT sustain elevated NAD+ levels, supporting DNA damage repair mechanisms.
Hyperactivated SIRT1 promotes cell survival by inhibiting apoptosis and enhancing cell cycle progression.
NAD+ metabolism influences the immune microenvironment, affecting the functionality of CD8+ T cells and tumor-associated B cells.
Targeting NAD+ metabolism can disrupt the survival advantages of cancer cells and alter the immunosuppressive environment.
Clinical Implications
Challenges such as tumor metabolic heterogeneity and the need for improved monitoring technologies must be addressed.
Conclusion
NAD+ metabolic reprogramming is integral to understanding chemoresistance in colorectal cancer.
